425

Professor Adrian HillBack to People

adrian-hill
Subjects: Public Health
Department: Medicine
Phone: 01865 617611

Background

Adrian Hill moved from Trinity College, Dublin to Magdalen as an undergraduate in 1978, for just a year, but rather liked Oxford and is still around. He read medicine and then undertook a DPhil in molecular medicine focused on the genetics of Pacific Islanders. He joined the then new Weatherall Institute of Molecular Medicine as a Wellcome Senior Fellow in 1988 and began work on immunogenetics in West Africa that led to his current interest in malaria vaccine design and development.

Teaching

He is academic lead for a course on Human and Veterinary Vaccinology, and directs a module on vaccinology for the MSc in Global Health Sciences.

Research Interests

He is Professor of Human Genetics and a Fellow by Special Election at Magdalen. He is Director of the Jenner Institute (www.jenner.ac.uk) which focuses on designing and developing vaccines for infectious diseases prevalent in developing countries, such as HIV/AIDS, malaria and tuberculosis. He also heads a group at the Wellcome Trust Centre for Human Genetics which studies genetic susceptibility factors for common bacterial diseases. He is a passionate believer in the power of molecular medicine to design and deliver new health care interventions that will improve the lives of the poorest billion in sub-Saharan Africa and elsewhere. His own vaccine research programme has developed one of the most promising potential vaccines for malaria which is currently in large scale trials in infants in sub-Saharan Africa.

Selected Publications

  • Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV. 2001. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357:2017-21. 326 citations
  • Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, Smarason A, Day NP, McPheat WL, Crook DW, Hill AV. 2002 MBL genotype and risk of invasive pneumococcal disease: a case-control study Lancet. 359:1569-73.
  • McConkey SJ, Reece WH, Moorthy VS, 24 co-authors, Hill AVS. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine 9:729-35.
  • McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine 10:1240-4.
  • Khor CC, Vannberg FO, Chapman SJ, 31 co-authors, Hill AV. 2010. CISH and susceptibility to infectious diseases. New England Journal of Medicine 362:2092-101 2 citations
  • Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One. 2013;8(3):e57726